Submitted by reuters8361 in business
Novo Nordisk <a href="https://www.reuters.com/markets/companies/NOVOb.CO" target="_blank">(NOVOb.CO)</a> and Eli Lilly <a href="https://www.reuters.com/markets/companies/LLY.N" target="_blank">(LLY.N)</a> both expect juggernaut sales for their diabetes and we…